Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | 待询 | 6-8周 | ||
50 mg | 待询 | 6-8周 | ||
100 mg | 待询 | 6-8周 |
产品描述 | Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes. |
体外活性 | Exposure to Guadecitabine significantly (p<0.05) up-regulates the constitutive levels of expression of HLA class I antigens, HLA-A2 allospecificity, and of the co-stimulatory molecule ICAM-1, on Mel 275 melanoma cells. Guadecitabine induces a significant (p<0.01) reduction in the constitutive methylation levels of CTA promoters in investigated cancer cells. Exposure to Guadecitabine induces the expression of investigated cancer/testis antigens in CTA-negative cancer cells. Guadecitabine induces strongly up-regulates the constitutive levels of MAGE-A3- and NY-ESO-1-specific mRNA expression in neoplastic cells of all histotypes investigated. Mean values of the percentage of demethylation induced by Guadecitabine in MAGE-A1 and NY-ESO-1 promoters are 57 and 30 %, in Mel 195, and 22 and 33 % in MZ-1257 RCC cells, respectively [2]. |
体内活性 | Guadecitabine is effective at retarding tumor growth. Guadecitabine induces much less toxicity as determined by mouse weight changes when given subcutaneously (SQ) compare to that with IP injections. While the tumors do not shrink in size with Guadecitabine treatment, they experience very minimal growth while the tumors treated with PBS only show substantial growth [3]. |
别名 | SGI-110 |
分子量 | 557.41 |
分子式 | C18H24N9O10P |
CAS No. | 929901-49-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Guadecitabine 929901-49-5 Others SGI110 SGI-110 SGI 110 Inhibitor inhibitor inhibit